<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03240237</url>
  </required_header>
  <id_info>
    <org_study_id>ID_CP_OPT2016-012_0</org_study_id>
    <nct_id>NCT03240237</nct_id>
  </id_info>
  <brief_title>CCM in Heart Failure With Preserved Ejection Fraction</brief_title>
  <acronym>CCM-HFpEF</acronym>
  <official_title>Cardiac Contractility Modulation Therapy in Subjects With Heart Failure With Preserved Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Impulse Dynamics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Impulse Dynamics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study will evaluate the efficacy and safety of CCM therapy in heart failure
      patients with baseline EF≥50% (HFpEF) who have New York Heart Association (NYHA) Class II or
      III symptoms despite appropriate medication.

      The terminology of the HF classification HFpEF is based on the 2016 European Society of
      Cardiology (ESC) Heart Failure Guidelines.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot clinical study of CCM in addition to optimal medical therapy (OMT) over a 24
      week period.The primary endpoint shall be mean change from baseline to 24 weeks in Kansas
      City Cardiomyopathy Questionnaire (KCCQ) overall score (reflecting integrated information on
      physical limitations, symptoms, self-efficacy, social interference and quality of life).

      This pilot study will collect efficacy and safety data in heart failure patients having NYHA
      class II and III symptoms despite appropriate medication with baseline ejection fraction
      equal or greater than 50% (HFpEF populations).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This pilot study is designed and powered for evaluating the efficacy and safety of CCM therapy in heart failure patients with baseline EF≥50% (HFpEF) who have NYHA Class II or III symptoms despite appropriate medication, for potential expansion of the CE Mark indication for use in the HFpEF population.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>KCCQ change</measure>
    <time_frame>24 weeks</time_frame>
    <description>Mean change from baseline to 24 weeks in Kansas City Cardiomyopathy Questionnaire (KCCQ) overall score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Echocardiography</measure>
    <time_frame>24 weeks</time_frame>
    <description>LAVi and diastolic function: septal E' velocity, septal E/E' ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NT-proBNP</measure>
    <time_frame>24 weeks</time_frame>
    <description>Mean Change in 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA class</measure>
    <time_frame>24 weeks</time_frame>
    <description>Mean Change in 24 weeks</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Heart Failure, Diastolic</condition>
  <arm_group>
    <arm_group_label>CCM therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Optimizer SMART</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optimizer SMART</intervention_name>
    <description>Cardiac Contractility Modulation</description>
    <arm_group_label>CCM therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Inclusion criteria

               1. Baseline ejection fraction ≥ 50% (as assessed by echocardiogram within 30 days of
                  enrollment and confirmed by the echo core laboratory).

               2. NYHA class II or III symptoms despite receiving stable optimal medical therapy
                  (OMT) for at least 30 days based on patient's medical records (chronic stable,
                  not transient or crescendo heart failure or angina pectoris)

               3. Stable optimal medical therapy for Heart failure for 3 months.

               4. NT-proBNP &gt; 220 pg/ml for subjects in sinus rhythm or &gt; 600 pg/ml for subjects in
                  atrial fibrillation

               5. Has the following (as assessed by the core lab):

                    -  LAVi ≥ 34 ml/m² or LVH &gt;12mm AND either

                    -  E/e' ≥ 13 OR

                    -  septal e' &lt; 7 cm/s or lateral e' &lt;10 cm/s

               6. Patient giving informed consent, willing to be available for scheduled study
                  follow-up visits, and able to complete all testing of the study protocol

          2. Exclusion criteria

               1. Age below 40 or greater than 80

               2. Patients with expected lifespan of less than 12 months from time of enrollment

               3. Subjects referred to an institution based on a judicial or administrative order

               4. Dilated left ventricle, as evidenced by LVEDVI &gt;= 97 mL/m2 (as assessed by the
                  echo core lab)

               5. Primary cardiac valvular disease (anything more than grade 2)

               6. Congenital or untreated ischemic heart disease

               7. Infiltrative / inflammatory / genetic cardiomyopathy as documented in the medical
                  record (e.g. amyloid, hemochromatosis, myocarditis, hypertrophic cardiomyopathy,
                  M. Fabry, cardiac tumor), or persistent large pericardial effusion

               8. Unstable or frequent (&gt;1 episode/week) angina pectoris

               9. Hospitalization for HF requiring the use of inotropic support or IABP within 30
                  days of enrollment

              10. Systolic Blood Pressure &gt; 160 mmHg

              11. Uncorrected severe anemia (e.g. hemoglobin &lt;9g/dL)

              12. PR interval greater than 375 ms

              13. Exercise tolerance limited due to noncardiac disorders (e.g. deconditioning,
                  severe lung disease, frailty)

              14. Scheduled for a cardiac surgery or a PCI procedure, or had a cardiac surgery
                  procedure within 90 days or a PCI procedure within 30 days prior to enrollment

              15. Myocardial infarction within 90 days of enrollment

              16. Cardioversion within 30 days of enrollment

              17. History of significant ectopy either on 12-lead ECG or Holter monitoring (more
                  than 10% PVCs).

              18. Heart rate &gt; 110 bpm on ECG for patients with atrial fibrillation

              19. Mechanical tricuspid valve

              20. Prior heart transplant or ventricular assist device

              21. Pregnant or planning to become pregnant during the study

              22. Breastfeeding subjects

              23. Subject participating in another medical therapy or device related study,
                  unrelated to CCM™, at the same time or within 30 days prior to enrollment into
                  this study

              24. Subjects on dialysis, or with documented GFR&lt;30 or with other major medical
                  disorder (e.g. severe anemia, liver failure)

              25. Subjects with any active non-cardiac implants
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carsten Tschoepe, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Charite Berlin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leah A Reddig</last_name>
    <phone>+49 711 220 456-0</phone>
    <phone_ext>+4907112204560</phone_ext>
    <email>l.reddig@impulse-dynamics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Friendly Society Private Hospital</name>
      <address>
        <city>Bundaberg</city>
        <state>Queensland</state>
        <zip>4670</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Fox</last_name>
      <email>karen.fox@genesiscare.com</email>
    </contact>
    <contact_backup>
      <last_name>Kassandra Howes</last_name>
      <email>Kassandra.Howes@genesiscare.com</email>
    </contact_backup>
    <investigator>
      <last_name>Hermann Wittmer, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andre Conradie, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David DiFiore</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Andrew´s Private Hospital</name>
      <address>
        <city>Adelaide</city>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Fragnito</last_name>
      <phone>+61882026600</phone>
      <email>kristen.fragnito@genesiscare.com</email>
    </contact>
    <contact_backup>
      <last_name>Kate Thring</last_name>
      <phone>+61 8 8202 6653</phone>
      <email>kate.thring@genesiscare.com</email>
    </contact_backup>
    <investigator>
      <last_name>Luay Samaraie, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Glenn Young, PD Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. John of God Bunbury</name>
      <address>
        <city>Bunbury</city>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine MacLean</last_name>
      <email>Katherine.MacLean@genesiscare.com</email>
    </contact>
    <contact_backup>
      <last_name>Jo Crittenden</last_name>
      <email>Jo.Crittenden@genesiscare.com</email>
    </contact_backup>
    <investigator>
      <last_name>Stefan Buchholz, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alison Morton</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. John of God Murdoch Hospital</name>
      <address>
        <city>Perth</city>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joy Vibert</last_name>
      <email>Joy.Vibert@genesiscare.com</email>
    </contact>
    <contact_backup>
      <last_name>Jo Crittenden</last_name>
      <email>Jo.Crittenden@genesiscare.com</email>
    </contact_backup>
    <investigator>
      <last_name>Peter Dias, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin King</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Purnell</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Na Homolce</name>
      <address>
        <city>Praha 5</city>
        <zip>15030</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petr Neuzil, Prof.</last_name>
      <phone>+420 257272211</phone>
      <email>petr.neuzil@homolka.cz</email>
    </contact>
    <contact_backup>
      <last_name>Pavla Drahovzalová, Ing.</last_name>
      <phone>+420 257 272 376</phone>
      <email>Pavla.Drahovzalova@homolka.cz</email>
    </contact_backup>
    <investigator>
      <last_name>Petr Neuzil, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>European Georges Pompidou Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <state>Bavaria</state>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Kerckhoff-Klinik GmbH</name>
      <address>
        <city>Bad Nauheim</city>
        <state>Hesse</state>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Rieth, Dr.</last_name>
      <phone>+ 49 6032 / 996 2677</phone>
      <email>A.Rieth@kerckhoff-klinik.de</email>
    </contact>
    <contact_backup>
      <last_name>Annerose Peil</last_name>
      <phone>+49 6032 996 2657</phone>
      <email>A.Peil@kerckhoff-klinik.de</email>
    </contact_backup>
    <investigator>
      <last_name>Andreas Rieth, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GFO-Kliniken Bonn, St.-Marien-Hospital Bonn</name>
      <address>
        <city>Bonn</city>
        <state>Rhine-Westphalia</state>
        <zip>53115</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dieter Bimmel, Dr.</last_name>
      <phone>+49 228 5052877</phone>
      <email>dieter.bimmel@marien-hospital-bonn.de</email>
    </contact>
    <contact_backup>
      <last_name>Christiane Lieberz</last_name>
      <phone>+49 228 5052729</phone>
      <email>christiane.lieberz@marien-hospital-bonn.de</email>
    </contact_backup>
    <investigator>
      <last_name>Dieter Bimmel, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charite Berlin Campus Virchow</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carsten Tschoepe, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Carsten Tschoepe, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Policlinico San Donato</name>
      <address>
        <city>Milan</city>
        <zip>20097</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlo Pappone, Prof.</last_name>
      <email>carlo.pappone@grupposandonato.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Multimedica</name>
      <address>
        <city>Milan</city>
        <zip>20099</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Sagone, Prof.</last_name>
      <email>antonio.sagone@multimedica.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadia Aspromonte, Dr.</last_name>
      <email>nadia.aspromonte@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Bortolo</name>
      <address>
        <city>Vicenza</city>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Barbati</last_name>
      <phone>'+39 338 4299446</phone>
      <email>giovanni.barbati@aulss8.veneto.it</email>
    </contact>
    <investigator>
      <last_name>Antonio Rossillo, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Public institution Vilnius University Hospital Santaros Klinikos</name>
      <address>
        <city>Vilnius</city>
        <zip>8661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gediminas Rackauskas, Dr.</last_name>
      <email>gediminas.rackauskas@santa.lt</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego zakład leczniczy Centralnego Szpitala Klinicznego</name>
      <address>
        <city>Warsaw</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renata Główczyńska, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Marcin Grabowski, Prof. Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>4 Wojskowy Szpital Kliniczny z Poliklinika SPZOZ we Wroclawiu</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-981</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bartek krakowiak, Dr.</last_name>
      <phone>+4871 766 03 73</phone>
      <email>bartek.krakowiak@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Bartek Krakowiak, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny we Wrocław</name>
      <address>
        <city>Wrocław</city>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Kołodziej, Dr</last_name>
      <phone>+48 606 721 336</phone>
      <email>dr.adamkolodziej@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Adam Kolodziej, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Lisbon Hospital Center, E.P.E., hereinafter referred to as CHLO, E.P.E</name>
      <address>
        <city>Lisbon</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Cândida Fonseca, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Santiago de Compostella -- Servicio de Cardiología y UCC/ Cardiology and Coronary Care Department Hospital Clínico Universitario. XXI de Santiago de Compostela SERGAS</name>
      <address>
        <city>Santiago De Compostela</city>
        <state>C/ A Choupana S.n</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Seijos Amigo</last_name>
      <phone>'+ 34 981 950 778/ 774</phone>
      <email>Jose.Seijas.Amigo@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Javier Garcia Seara, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>3010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raquel Ajo Ferrer</last_name>
      <phone>+34 965 91 36 78</phone>
      <email>ajo_raq@gva.es</email>
    </contact>
    <investigator>
      <last_name>Juan Grabriel Martinez, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre Unidad de Insuficiencia Cardiaca y Trasplante Servicio de Cardiología, Planta 6. Bloque D.Ciber 8</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nuria Ochoa Parra</last_name>
      <phone>34917792642</phone>
      <email>nuriaochoaparra@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Juan Delgado Jiménez, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital Alvaro Cunquero</name>
      <address>
        <city>Vigo</city>
        <zip>36312</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia Soto Fernández</last_name>
      <phone>+34 986 825 564</phone>
      <email>Investigacion.Cardiovascular3.Vigo@sergas.es</email>
    </contact>
    <investigator>
      <last_name>ElvisTeijeira Fernandez, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helena Karlsson</last_name>
    </contact>
    <investigator>
      <last_name>Cecilia Linde, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Sweden</country>
  </location_countries>
  <results_reference>
    <citation>Tschöpe C, Van Linthout S, Spillmann F, Klein O, Biewener S, Remppis A, Gutterman D, Linke WA, Pieske B, Hamdani N, Roser M. Cardiac contractility modulation signals improve exercise intolerance and maladaptive regulation of cardiac key proteins for systolic and diastolic function in HFpEF. Int J Cardiol. 2016 Jan 15;203:1061-6. doi: 10.1016/j.ijcard.2015.10.208. Epub 2015 Oct 27.</citation>
    <PMID>26638055</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 2, 2017</study_first_submitted>
  <study_first_submitted_qc>August 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2017</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HFpEF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Diastolic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

